Previous studies by Bayer's lab revealed that inhibiting CaMKII activity protects against some of the effects of amyloid-beta (Abeta) plaques in the brain, a hallmark of Alzheimer's disease (AD).

Novartis Pharma AG (Basel, Switzerland) Head of BACE Inhibitors Project 1997 – 1999. Novartis Pharma AG (Basel, Switzerland) Head of Abeta Generation Project 1992 – 1997. Sandoz Research Institute ...

Recently approved Alzheimer's drugs work by tagging amyloid plaques for clearance by the brain's microglia. Washington ...

Most of my current research is in Alzheimer's disease and concerns the metabolism and clearance of soluble, insoluble and oligomeric forms of Abeta, alterations in Abeta-degrading enzymes, impairment ...

Sabirnetug is under clinical development by Acumen Pharmaceuticals and currently in Phase I for Dementia Associated With Alzheimer's Disease.

But over the... AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn ...